Charles Lopez

Associate Professor

893 Citations
16 h-Index

If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Charles Lopez is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

5 Similar Profiles

Apoptosis Medicine & Life Sciences

Colorectal Neoplasms Medicine & Life Sciences

irinotecan Medicine & Life Sciences

Neoplasms Medicine & Life Sciences

gemcitabine Medicine & Life Sciences

Pancreatic Neoplasms Medicine & Life Sciences

Proteins Medicine & Life Sciences

Drug Therapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2000 2010

2 Finished

Mechanisms linking ASPP2 to the Rb/E2F and p53 pathways

Lopez, C.

National Institutes of Health

9/1/04 → 6/30/10

Project: Research project

Apoptosis

Proteins

Neoplasms

P53 AND UV REGULATION OF P53 BINDING PROTEIN BBP/53BP2

Lopez, C.

National Institutes of Health

6/7/00 → 5/31/05

Project: Research project

Carrier Proteins

Proteins

DNA Damage

Neoplasms

Up-Regulation

Research Output 1990 2019

893 Citations
16 h-Index
32 Article
3 Review article

8 Citations (Scopus)

Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma

Allen-Petersen, B. L., Risom, T., Feng, Z., Wang, Z., Jenny, Z. P., Thoma, M. C., Pelz, K. R., Morton, J. P., Sansom, O. J., Lopez, C., Sheppard, B., Christensen, D. J., Ohlmeyer, M., Narla, G. & Sears, R., Jan 1 2019, In : Cancer Research. 79, 1, p. 209-219 11 p.

Research output: Contribution to journal › Article

Protein Phosphatase 2

Adenocarcinoma

Phosphoric Monoester Hydrolases

Phosphotransferases

Growth

Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia

Schittenhelm, M. M., Walter, B., Tsintari, V., Federmann, B., Bajrami Saipi, M., Akmut, F., Illing, B., Mau-Holzmann, U., Fend, F., Lopez, C. & Kampa-Schittenhelm, K. M., Apr 1 2019, In : EBioMedicine. 42, p. 340-351 12 p.

Research output: Contribution to journal › Article

Open Access

Tumor Suppressor Protein p53

Alternative Splicing

Tumors

Protein Isoforms

Leukemia

A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer

Kearney, M. R., Chen, E. Y., Vaccaro, G., Strother, J., Burt, A., Todd, K., Donovan, J., Kampa-Schittenhelm, K. M. & Lopez, C., Jan 1 2019, In : Anticancer Research. 39, 1, p. 245-252 8 p.

Research output: Contribution to journal › Article

irinotecan

Colorectal Neoplasms

oxaliplatin

Neutropenia

Combination Drug Therapy

Evolving Treatment Options and Future Directions for Locally Advanced Rectal Cancer

Chen, E. Y., Kardosh, A., Nabavizadeh, N. & Lopez, C., Jan 1 2019, In : Clinical Colorectal Cancer.

Research output: Contribution to journal › Review article

Rectal Neoplasms

Neoadjuvant Therapy

Radiation-Sensitizing Agents

Neoplasm Metastasis

Drug Therapy

5 Citations (Scopus)

A Phase II Study of Celecoxib with Irinotecan, 5-Fluorouracil, and Leucovorin in Patients with Previously Untreated Advanced or Metastatic Colorectal Cancer

Chen, E. Y., Blanke, C., Haller, D. G., Benson, A. B., Dragovich, T., Lenz, H. J., Robles, C., Li, H., Mori, M. T., Mattek, N., Sanborn, R. E. & Lopez, C., Dec 1 2018, In : American Journal of Clinical Oncology: Cancer Clinical Trials. 41, 12, p. 1193-1198 6 p.

Research output: Contribution to journal › Article

irinotecan

Celecoxib

Leucovorin

Fluorouracil

Colorectal Neoplasms